Compare
Outset Medical, Inc. vs Biolife Solutions Inc vs Vaso Corp vs Ceribell, Inc.
| Latest fiscal year | Outset Medical, Inc. OM | Biolife Solutions Inc BLFS | Vaso Corp VASO | Ceribell, Inc. CBLL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $119.48M | $96.21M | $89.10M | $89.06M |
| Revenue growth (YoY) | +5.1% | +28.9% | +2.7% | +36.1% |
| Gross margin | 39.1% | 64.6% | 61.4% | 87.9% |
| Operating margin | -55.8% | -17.3% | -3.2% | -65.6% |
| Net margin | -68.3% | -4.8% | 1.8% | -60.0% |
| Net income | -$81.65M | -$4.59M | $1.57M | -$53.41M |
| EPS (Diluted) | -$5.37 | -$0.10 | $0.01 | -$1.46 |
| Operating cash flow | -$46.33M | $20.11M | $9.27M | -$40.81M |
| Free cash flow | -$47.12M | $10.64M | n/a | -$41.58M |
| Cash & equivalents | $35.01M | $33.04M | $35.05M | $40.48M |
| Total assets | $264.50M | $405.88M | $88.35M | $195.80M |
| Total liabilities | $137.54M | $34.00M | n/a | $40.47M |
| Shareholders' equity | $126.95M | $371.89M | $29.43M | $155.34M |
| Return on year-end equity | -64.3% | -1.2% | 5.3% | -34.4% |
| Shares outstanding | 18.17M | 48.20M | 175.95M | 37.49M |
Revenue, most recent five fiscal years
| Fiscal year | Outset Medical, Inc. | Biolife Solutions Inc | Vaso Corp | Ceribell, Inc. |
|---|---|---|---|---|
| Latest | $119.48M Ended 2025-12-31 | $96.21M Ended 2025-12-31 | $89.10M Ended 2025-12-31 | $89.06M Ended 2025-12-31 |
| 1 year earlier | $113.69M Ended 2024-12-31 | $74.65M Ended 2024-12-31 | $86.77M Ended 2024-12-31 | $65.44M Ended 2024-12-31 |
| 2 years earlier | $130.38M Ended 2023-12-31 | $68.02M Ended 2023-12-31 | $81.02M Ended 2023-12-31 | $45.23M Ended 2023-12-31 |
| 3 years earlier | $115.38M Ended 2022-12-31 | $76.24M Ended 2022-12-31 | $79.29M Ended 2022-12-31 | n/a |
| 4 years earlier | $102.60M Ended 2021-12-31 | $119.16M Ended 2021-12-31 | $75.58M Ended 2021-12-31 | n/a |